Finding good leaders always has been hard, but record-breaking VC investment and IPOs, COVID-19 and diversity initiatives have compounded the growing problem.
Industry’s run of raising enormous amounts of cash for new and growing biopharmaceutical companies has created a double-edged sword, producing a shortage of talent to run these firms and to oversee research and development pipelines fueled by record-breaking levels of venture capital investment and initial public offerings.
Biopharma’s talent crisis has been impacted by COVID-19 in important ways as well. Companies had to rapidly hire additional employees...
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
